PREPRINT (not peer reviewed)

Global Increases in Brain Glucose Metabolism Following Acute N,N-Dimethyltryptamine and Harmine Administration in Healthy Volunteers: An [¹⁸F]FDG-PET Study

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Research Square
Date: 2025-07-27
Source: Europe PMC
DOI: 10.21203/rs.3.rs-7099164/v1
PubMed: Unavailable

Authors

Egger K Bozsak R Aicher H Sari H Poetzsch S Rominger A Martin-Soelch C Dornbierer D Quednow B Scheidegger M Cumming P.

Watch author

Derived topics and classifications

psilocybin Brain Imaging Pharmacology Receptor Pharmacology Consciousness Aging Healthy Volunteers Other

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Psilocybin Administration With 5-HT1a BlockadeClinicalTrials.gov · 2026-08-14 Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy VolunteersClinicalTrials.gov · 2026-02-05 Open Label Psilocybin Brain Stimulation and Imaging Pilot StudyClinicalTrials.gov · 2026-08-07 A Double Blind, Randomized Trial Investigating the Safety, Feasibility, and Mechanisms of Psychedelics in Healthy Older Adults With Low Well-being as Moderated by Biomarkers for Preclinical Alzheimer's DiseaseClinicalTrials.gov · 2026-06-08 Multivariate Neural and Physiological Correlates of Psychedelic Sub-states: a Within-subjects, Healthy Volunteer Study With Experience-samplingClinicalTrials.gov · 2026-06-05 A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 (Psilocybin) in Healthy ParticipantsClinicalTrials.gov · 2025-06-12 A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 (psilocybin) in Healthy ParticipantsClinicalTrials.gov · 2024-10-09 Investigation of Psychedelic Effects in Psychoactive SubstancesClinicalTrials.gov · 2026-02-23